Long-term safety and efficacy of antibody ALXN2220 for depletion of cardiac amyloid transthyretin: results of treatment beyond 12 months in the open-label extension of study NI006-101

Back

ESC Premium Access

Long-term safety and efficacy of antibody ALXN2220 for depletion of cardiac amyloid transthyretin: results of treatment beyond 12 months in the open-label extension of study NI006-101

Session: Advances in amyloidosis

Topic: Pharmacotherapy

Speaker: Professor P. Van Der Meer (Groningen, NL)

Event: ESC Congress 2024

Congress Presentation

About the speaker

Professor Peter Van Der Meer

University Medical Centre Groningen, Groningen (Netherlands (The))

56 presentations

3 followers

4 more presentations in this session

Patient journey from the appearance of red flags to the diagnosis of transthyretin cardiac amyloidosis (ATTR-CM) in Japan: a nationwide retrospective study using a medical claims database

Speaker: Doctor H. Abe (JP)

Long-term all-cause and cardiovascular-related mortality in patients with ATTR-CM treated with continuous tafamidis vs placebo to tafamidis by NAC stage at baseline

Speaker: Professor M. Fontana (London, GB)

Tafamidis for the treatment of transthyretin cardiac amyloidosis (ATTR-CM) - Real-world data from a tertiary center.

Speaker: Doctor R. Carvalho (Lisbon, PT)

Long-term effects of patisiran on survival and cardiac parameters in patients with transthyretin-mediated cardiac amyloidosis: post hoc analysis of APOLLO-B and cardiac subpopulation of APOLLO OLE

Speaker: Professor O. Lairez (Toulouse, FR)

Access the full session

Advances in amyloidosis

Speakers: Professor P. Van Der Meer, Doctor H. Abe, Professor M. Fontana, Doctor R. Carvalho, Professor O. Lairez

Access

Video

About the event

ESC Congress 2024

30 August - 2 September 2024

Sessions Presentations

Congress

ESC 365 is supported by

Explore sponsored resources